Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

French Trial Tragedy: US FDA Launches Safety Probe Of FAAH Inhibitors

This article was originally published in SRA

Executive Summary

US regulators are conducting a safety probe of fatty acid amide hydrolase (FAAH) inhibitors being developed and studied in the US, following the clinical trial tragedy in France where one healthy volunteer testing a product in that class died and five other participants experienced severe adverse neurological events1.

Advertisement
Advertisement
UsernamePublicRestriction

Register